AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pasithea Therapeutics Corp. Director's Dealing 2022

Aug 15, 2022

35389_dirs_2022-08-15_0b09d718-2b68-4ada-9606-ffdda980ec52.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2022-08-09

Reporting Person: Shahinian Eric (Member of 10% owner group)
Reporting Person: Camac Capital, LLC (Member of 10% owner group)
Reporting Person: Camac Fund, LP (Member of 10% owner group)
Reporting Person: Camac Partners, LLC (Member of 10% owner group)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1455556	Indirect

Footnotes

F1: The shares are held by Camac Fund, LP. ("Camac Fund"). Eric Shahinian is the managing member of Camac Capital, LLC, which is the general partner of Camac Fund and the managing member of Camac Partners, LLC.